11 unchanged sentences
Purchased Under
−Removed: July 1, 2021 – July 31, 2021 937 (1)
+Added: January 1, 2022 - January 31, 2022 715 (1)
— $2,523,316,993
−Removed: August 1, 2021 – August 31, 2021 898 (1)
+Added: February 1, 2022 - February 28, 2022 6,653,483 (1)
6,652,791 $1,550,785,350
−Removed: September 1, 2021 – September 30, 2021 1,011 (1)
+Added: March 1, 2022 - March 31, 2022 1,048,640 (1)
1,048,000 $1,393,714,917
1 unchanged sentence
7,700,791 $1,393,714,917
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 937 in July;
−Removed: 898 in August;
−Removed: and 1,011 in September.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 715 in January;
+Added: 692 in February;
+Added: and 640 in March.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
2 unchanged sentences
Exhibit Description
+Added: Form of AbbVie Inc.
+Added: Performance-Vested Restricted Stock Unit Agreement*
+Added: Form of AbbVie Inc.
+Added: Performance Share Award Agreement*
+Added: Form of AbbVie Inc.
+Added: Non-Employee Director RSU Agreement (US) *
+Added: Form of AbbVie Inc.
+Added: Non-Qualified Stock Option Agreement *
+Added: Form of AbbVie Inc.
+Added: Retention RSU Agreement – Ratable Vesting*
+Added: Form of AbbVie Inc.
+Added: Retention RSU Agreement – Cliff Vesting with Dividend Equivalent Accrual *
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 2, 2021, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed on May 6, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
6 unchanged sentences
Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).
+Added: _______________________________________________________________________________
+Added: * Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
2022 Form 10-Q |
1 unchanged sentence
/s/ Robert A.
−Removed: Executive Vice President,
−Removed: Chief Financial Officer
−Removed: November 2, 2021
+Added: Vice Chairman, Finance and Commercial Operations and
+Added: Chief Financial Officer (Principal Financial Officer)
2022 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.